QuidelOrtho Corporation (QDEL) Income Statement

The revenue series appears to be drifting lower from the $700M-plus range seen in late 2025 and early 2025 toward the $620M level, which suggests the respiratory testing tailwind has largely unwound. Growth durability looks questionable because the segment mix leans on the Point-of-Care business, whose volume is seasonal and tied to flu, RSV and COVID cycles. Investors should monitor whether Labs and Transfusion Medicine can offset this decline or whether the contraction becomes structural.

The partial rebound in gross margin may reflect a shift in product mix and cost absorption following the post-merger integration, though the reported data do not isolate these drivers. The persistent gap versus higher-margin diagnostic peers suggests limited pricing power in the clinical chemistry franchise. Margin direction is encouraging on a quarterly basis but does not yet demonstrate durable structural improvement.

Because SG&A has not declined meaningfully even as revenue contracted, operating leverage is working against the company rather than for it. The gap between gross profit of roughly $290M and operating income of roughly -$7.5M implies that overhead consumes close to the entire gross profit pool. Management's ability to right-size the cost base will likely determine whether operating income can turn sustainably positive.